Reduction of liver stiffness by antiviral therapy in chronic hepatitis B

Osakabe, Keisuke; Ichino, Naohiro; Nishikawa, Toru; Sugiyama, Haruko; Kato, Miyako; Kitahara, Shiho; Hashimoto, Senju; Kawabe, Naoto; Harata, Masao; Nitta, Yoshifumi; Murao, Michihito; Nakano, Takuji; Shimazaki, Hiroaki; Arima, Yuko; Suzuki, Kôji; Yoshioka, Kentaro

doi:10.1007/s00535-011-0444-4

Cited by 50 publications

(46 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, multivariate analysis revealed that longer antiviral therapy duration prior to the initial LSM was associated with an improvement in liver fibrosis. It appears that in cirrhotic CHB patients, the duration of oral NA intake and the amount of viral replication significantly affect the efficacy of antiviral therapy, which is supported by the findings by Osakabe et al (11). The main limitation of the present study was that no liver histology was available for this cohort.…”

Section: Discussionmentioning

confidence: 53%

See 1 more Smart Citation

Changes in liver stiffness and its associated factors during oral antiviral therapy in Chinese patients with chronic hepatitis B

Jin

Zhang

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 53%

“…For instance, liver fibrosis improved in 35-38% of lamivudine-treated CHB patients and 36-39% of ETV-treated CHB patients after 1 year (9,10). Long-term ETV treatment (>3 years) attenuated necroinflammatory activity in all patients and reduced liver fibrosis in 57-100% of patients (11,12).…”

Section: Discussionmentioning

confidence: 93%

Changes in liver stiffness and its associated factors during oral antiviral therapy in Chinese patients with chronic hepatitis B

Jin

Zhang

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…For instance, liver fibrosis has been reported to improve in 35-38% of lamivudine-treated CHB patients and 36-39% of ETV-treated CHB patients after one year (12,13). Long-term ETV treatment (>3 years) attenuated necroinflammatory activity in all patients and reduced liver fibrosis in 57-100% of patients (1,14). Furthermore, advanced liver fibrosis was shown to be reversed after long-term antiviral treatment (14,15).…”

Section: Discussionmentioning

confidence: 98%

“…The ultimate goal for treating CHB is to block the advancement of chronic liver injury to the stages of cirrhosis, hepatic decompensation and/or hepatocellular carcinoma (HCC). Thus, an early and accurate diagnosis of fibrosis stages is important for assessing prognosis (1)(2)(3).…”

Section: Introductionmentioning

confidence: 99%

Chronic hepatitis B patients with high liver fibrosis levels should receive antiviral treatment

Jin

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The present study aimed to evaluate improvements in liver stiffness (LS) measured by transient elastography (TE) and associated factors in Chinese patients with chronic hepatitis B (CHB) treated with entecavir (ETV). A total of 190 consecutive CHB patients who received entecavir therapy and two LS measurements (LSMs) were enrolled in this retrospective study (average age, 47 years; 137 males [72.1%]), including 111 patients without liver cirrhosis (group 0) and 79 patients with liver cirrhosis (group 1). Each patient received LSM twice with an interval of six months. Normalized aspartate aminotransferase (AST) levels were accompanied by a significant reduction in LSM values (P<0.001) in each group. Multivariate analysis revealed that a higher initial LS value in groups 0 and 1, and a higher prothrombin time activity in group 1 was associated with a greater decline of the LS value. Higher initial quantitative hepatitis B surface antigen (qHBsAg) levels were correlated with a greater decline of the qHBsAg value in the two groups. In conclusion, LS values in CHB patients significantly improved after 24 weeks of entecavir therapy. The results suggested that higher LSM values at baseline contributed to a greater regression of LSM, and higher initial qHBsAg values could lead to greater qHBsAg reduction during ETV therapy. Extrapolating our results, we might be able to consider CHB patients who have higher initial LSM values or have higher levels of qHBsAg values when enrolled would have more benefit during ETV treatment.

show abstract

“…[15] Antiviral therapy is also one of the important means to delay and reverse liver fibrosis induced by chronic hepatitis B. [16] Adefovir Dipivoxil, as an antiviral agent of nucleoside commonly used in clinic, has a strong role in inhibiting HBV-DNA replication, [17] and it can reduce liver inflammation, promote the recovery of liver function and prevent liver fibrosis progression, and its resistance rate is low. [18] In 2007, in the CBH Prevention Guide proposed by the American Association for the Study of Liver Diseases (AASID), moderate to severe inflammation or obvious liver fibrosis shown by liver biopsy is recommended as one of the indications of antiviral therapy.…”

Section: Discussionmentioning

confidence: 99%

Clinical Effects of Safflower Pill of Dedu Seven Medicinal Herbs Plus Adefovir Dipivoxil on Liver Fibrosis Resulting from Chronic Viral Hepatitis B

Na¹

2017

IJBSE

View full text Add to dashboard Cite

Abstract:To study the clinical effects of Safflower Pill of Dedu Seven Medicinal Herbs combined with Adefovir Dipivoxil on liver fibrosis resulting from chronic viral hepatitis B.116 patients with chronic hepatitis B fibrosis were randomly divided into two groups (n=58 for each group): treatment group (Safflower Pill of Seven Medicinal Herbs combined with Adefovir Dipivoxil) and control group (Adefovir Dipivoxil) (n=58) for clinical observation of 24 weeks. After 24 weeks, the effective rates were 93.10% and 81.03% in the treatment group and control group respectively; the indexes of liver function, liver fibrosis and radiographic indexes of the patients in both groups were significantly decreased (P<0.05 or P<0.01); The differences between the two groups were statistically significant (P<0.05). The effect of Safflower Pill of Seven Medicinal Herbs combined with Adefovir Dipivoxil for the treatment of chronic hepatitis B fibrosis is more effective than that of Adefovir Dipivoxil alone.

show abstract

Reduction of liver stiffness by antiviral therapy in chronic hepatitis B

Cited by 50 publications

References 38 publications

Changes in liver stiffness and its associated factors during oral antiviral therapy in Chinese patients with chronic hepatitis B

Changes in liver stiffness and its associated factors during oral antiviral therapy in Chinese patients with chronic hepatitis B

Chronic hepatitis B patients with high liver fibrosis levels should receive antiviral treatment

Clinical Effects of Safflower Pill of Dedu Seven Medicinal Herbs Plus Adefovir Dipivoxil on Liver Fibrosis Resulting from Chronic Viral Hepatitis B

Contact Info

Product

Resources

About